Skip to main content

BeOne Medicines Ltd.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

ONC$417.33+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Form 10‑K to be signed on its behalf by the undersigned, thereunto duly authorized.

BEONE MEDICINES LTD.
Date: February 26, 2026By:/s/ JOHN V. OYLER
John V. Oyler
Chief Executive Officer and Chairman
(Principal Executive Officer)

POWER OF ATTORNEY

Each person whose individual signature appears below hereby authorizes and appoints John V. Oyler, Aaron Rosenberg and Chan Lee, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney‑in‑fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10‑K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys‑in‑fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys‑in‑fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10‑K has been signed by the following persons in the capacities indicated below and on the dates indicated:

SignatureTitleDate
/s/ JOHN V. OYLERChief Executive Officer and ChairmanFebruary 26, 2026
John V. Oyler(Principal Executive Officer)
/s/ AARON ROSENBERGChief Financial OfficerFebruary 26, 2026
Aaron Rosenberg(Principal Financial Officer)
/s/ TITUS BALLChief Accounting OfficerFebruary 26, 2026
Titus Ball(Principal Accounting Officer)
/s/ OLIVIER BRANDICOURTDirectorFebruary 26, 2026
Olivier Brandicourt
/s/ MARGARET DUGANDirectorFebruary 26, 2026
Margaret Dugan
/s/ MICHAEL GOLLERDirectorFebruary 26, 2026
Michael Goller
/s/ ANTHONY C. HOOPERDirectorFebruary 26, 2026
Anthony C. Hooper
/s/ RANJEEV KRISHANADirectorFebruary 26, 2026
Ranjeev Krishana
/s/ ALESSANDRO RIVADirectorFebruary 26, 2026
Alessandro Riva
/s/ CORAZON (CORSEE) D. SANDERSDirectorFebruary 26, 2026
Corazon (Corsee) D. Sanders
/s/ SHALINI SHARPDirectorFebruary 26, 2026
Shalini Sharp
/s/ XIAODONG WANGDirectorFebruary 26, 2026
Xiaodong Wang
/s/ QINGQING YIDirectorFebruary 26, 2026
Qingqing Yi
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.